go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Daiichi Sankyo Ireland Ltd

Daiichi Sankyo Ireland Ltd
Building 1, Swift Square, Northwood Avenue, Santry, Dublin 9, Ireland
Telephone: +353 1 489 3000
Fax: +353 1 489 3033
Medical Information e-mail: medinfo@daiichi-sankyo.ie
Summary of Product Characteristics last updated on medicines.ie: 10/10/2011
SPC Beneprav 10mg, 20mg, 40mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 10/10/2011 and displayed until Current
Reasons for adding or updating:
  • Change to joint SPC covering all presentations
Date of revision of text on the SPC:   01-Jul-2011
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



Section 2 - Addition of text in red
Each tablet contains 10 mg pravastatin sodium.

 

 

 

Each tablet contains 64.45 mg of lactose monohydrate.

 

 

 

 

Each tablet contains 20 mg pravastatin sodium.

 

 

 

Each tablet contains 128.9 mg of lactose monohydrate.

 

 

 

 

Each tablet contains 40 mg pravastatin sodium.

 

 

 

Each tablet contains 257.8 mg of lactose monohydrate.

 

 

 

 

Section 4.2 - Amendment to text in red

 

Children and adolescents (8-18 years of age):

 

For adolescents (14-18 years of age), the recommended dose range is 10-40 mg once daily. In children (8-13 years of age), the maximum recommended dose is 10 - 20 mg once daily, as doses greater than 20 mg have not been studied in this population (for children and adolescent females of child-bearing potential, see also section 4.6; for results of the study see section 5.1).

 

 

 

Section 10 - Change to date of revision of text

 

July 2010

 

 

 

 

 

Updated on 08/09/2010 and displayed until 10/10/2011
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   30-Aug-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

In Section 4.4, the following text has been added:

Interstitial lung disease:

Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.

In Section 4.8, the following text in red has been added:

Dizziness, headache, sleep disturbance, insomnia, nightmares

In Section 4.8, the following text has been added:


The following adverse events have been reported with some statins:

·         Memory loss

·         Sexual dysfunction

·         Depression

·         Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4)


In section 10, the following text has been changed:

August 2010

Updated on 07/07/2010 and displayed until 08/09/2010
Reasons for adding or updating:
  • Addition of joint SPC covering all presentations
Date of revision of text on the SPC:  
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

None provided

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Pravastatin Sodium

Versions

 
10/10/2011 to Current
08/09/2010 to 10/10/2011
07/07/2010 to 08/09/2010
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo